Mind Medicine (MindMed) Inc.

Equities

MNMD

CA60255C8850

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-07-05 pm EDT			5-day change	1st Jan Change
7.08 ^USD	-0.84%		-1.80%	+93.44%

Jul. 01	Mind Medicine Inc.(NasdaqGS:MNMD) added to Russell Small Cap Completeness Index	CI
Jul. 01	Mind Medicine Inc.(NasdaqGS:MNMD) added to Russell 2000 Index	CI

Mind Medicine Inc. Announces the Departure of Schond Greenway as Chief Financial Officer

May 08, 2024 at 04:10 pm EDT

On May 3, 2024, Mind Medicine (MindMed) Inc. made a transition in the role of Chief Financial Officer resulting in the departure of Schond Greenway. MindMed has retained an executive search firm to assist in identifying a new Chief Financial Officer.

Latest news about Mind Medicine (MindMed) Inc.

Mind Medicine Inc.(NasdaqGS:MNMD) added to Russell Small Cap Completeness Index	Jun. 30	CI
Mind Medicine Inc.(NasdaqGS:MNMD) added to Russell 2000 Index	Jun. 30	CI
Mind Medicine Inc.(NasdaqGS:MNMD) added to Russell 3000E Index	Jun. 30	CI
Mind Medicine Inc.(NasdaqGS:MNMD) added to Russell 3000 Growth Index	Jun. 30	CI
Mind Medicine Inc.(NasdaqGS:MNMD) added to Russell 3000E Growth Index	Jun. 30	CI
Mind Medicine Inc.(NasdaqGS:MNMD) added to Russell 2000 Growth Index	Jun. 30	CI
Mind Medicine Inc.(NasdaqGS:MNMD) added to Russell 2000 Dynamic Index	Jun. 30	CI
Mind Medicine Inc.(NasdaqGS:MNMD) dropped from Russell Microcap Value Index	Jun. 30	CI
Mind Medicine Inc.(NasdaqGS:MNMD) added to Russell 2500 Growth Index	Jun. 30	CI
Mind Medicine Inc.(NasdaqGS:MNMD) added to Russell Small Cap Comp Growth Index	Jun. 30	CI
Mind Medicine Inc.(NasdaqGS:MNMD) added to Russell 2500 Index	Jun. 30	CI
Mind Medicine Inc.(NasdaqGS:MNMD) added to Russell 3000 Index	Jun. 30	CI
Mind Medicine Inc.(NasdaqGS:MNMD) dropped from Russell 3000E Value Index	Jun. 30	CI
Mind Medicine to Join Russell 2000, 3000 Indexes	Jun. 28	MT
Mind Medicine Inc.(NasdaqGS:MNMD) added to S&P Pharmaceuticals Select Industry Index	Jun. 23	CI
Mind Medicine Inc Announces Constructive End-of-Phase 2 Meeting with U.S. FDA for MM120 in Generalized Anxiety Disorder	Jun. 20	CI
Sector Update: Health Care Stocks Steady Premarket Wednesday	Jun. 05	MT
Mind Medicine Shares Fall After FDA Committee Votes Against Lykos Therapeutics' Psychedelic Drug	Jun. 05	MT
Top Premarket Decliners	Jun. 05	MT
Baird Starts Mind Medicine (MindMed) With Outperform Rating, $27 Price Target	May. 29	MT
Oppenheimer Adjusts Mind Medicine Price Target to $20 From $29, Maintains Outperform Rating	May. 13	MT
Transcript : Mind Medicine Inc., Q1 2024 Earnings Call, May 08, 2024	May. 08
Mind Medicine Inc. Announces the Departure of Schond Greenway as Chief Financial Officer	May. 08	CI
Mind Medicine Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 08	CI
Leerink Partners Starts Mind Medicine (MindMed) With Outperform Rating, $20 Price Target	Apr. 15	MT

Chart Mind Medicine (MindMed) Inc.

Duration

Period

More charts

Company Profile

Mind Medicine (MindMed) Inc. is a clinical-stage biopharmaceutical company, which is engaged in developing products to treat brain health disorders. It is developing a pipeline of product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways. This specifically includes pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM-120 and MM-402, the Company's product candidates. MM120, is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that it is developing for the treatment of generalized anxiety disorder (GAD). MM-120 is also being studied in a subperceptual repeat administration dosing regimen for the treatment of attention deficit hyperactivity disorder (ADHD). MM-402, also referred to as R(-)-MDMA, is the Company's form of the R-enantiomer of 3,4-methylenedioxymethampheta (MDMA), which the Company is developing for the treatment of autism spectrum disorder (ASD).

Sector

Biotechnology & Medical Research

Calendar

2024-08-07 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

7.08 USD

Average target price

24.25 USD

Spread / Average Target

+242.51%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
MIND MEDICINE (MINDMED) INC.	+93.44%	509M
MODERNA, INC.	+18.97%	45.34B
LONZA GROUP AG	+41.98%	40.42B
IQVIA HOLDINGS INC.	-10.06%	37.92B
ALNYLAM PHARMACEUTICALS, INC.	+31.15%	31.75B
CELLTRION, INC.	-7.79%	27.71B
ICON PUBLIC LIMITED COMPANY	+13.32%	26.52B
UNITED THERAPEUTICS CORPORATION	+43.05%	13.96B
MEDPACE HOLDINGS, INC.	+31.28%	12.44B
BIO-TECHNE CORPORATION	-7.41%	11.26B

Other Biotechnology & Medical Research